Pharmaceutical Preparations
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Sector
ABBV
ABCL
ABT
ABUS
ACAD
AGIO
AKRO
ALKS
ALNY
ALPN
AMPH
AMRN
AMRX
ANAB
ANIP
ARCT
ARDX
ARQT
ARVN
ARWR
AUPH
AVDL
AVIR
AVTE
AXSM
BBIO
BCYC
BGNE
BHVN
BMEA
BMY
BPMC
CDMO
CERE
CMPS
CNTA
COGT
COLL
CORT
CPRX
CRNX
CYRX
CYTK
DAWN
DCPH
DVAX
DYN
ELAN
EOLS
ERAS
ETNB
EWTX
FOLD
GERN
GPCR
HRMY
HROW
HZNP
IDYA
IGMS
INSM
INVA
IONS
IRON
IRWD
ITCI
JANX
JAZZ
JNJ
KALV
KNSA
KROS
KURA
LGND
LLY
LQDA
LXRX
LYEL
MDGL
MIRM
MLTX
MLYS
MNKD
MORF
MRK
MRUS
MRVI
NRIX
OCUL
OGN
OLMA
OPK
ORGO
ORIC
PAHC
PBAJ
PBH
PCRX
PFE
PGEN
PHAT
PLRX
PRGO
PRTA
PTCT
PTGX
Discounted Cash Flow Valuation of Biomarin Pharmaceutical Inc
Growth
%
%
Discount
%
%
Multiple
g\r | +10% | +11% | +12% | +13% | +14% |
---|---|---|---|---|---|
0% | 10 | 9 | 8 | 8 | 7 |
+1% | 11 | 10 | 9 | 8 | 8 |
+2% | 13 | 11 | 10 | 9 | 8 |
+3% | 14 | 13 | 11 | 10 | 9 |
+4% | 17 | 14 | 12 | 11 | 10 |
Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF | $181.8M | $170M | $159M | $148.7M | $139.1M | $130.1M | $121.7M | $113.8M | $106.4M | $99.51M | $93.07M | $930.7M |
DCF | $147.9M | $120.2M | $97.79M | $79.53M | $64.67M | $52.6M | $42.77M | $34.78M | $28.29M | $23M | $230M | |
Value | $921.6M |
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | -19% | -56% | -8.9% | -5.2% | -1.4% | 46% | -3.5% | 6.8% | 6.9% | 8.3% |
ROA | -3% | -20% | 0.15% | -2.2% | -1.5% | -0.22% | -1.3% | 2.3% | 2.8% | 3.4% |
ROE | -7.2% | -23% | -4.2% | -2.6% | -0.76% | 21% | -1.5% | 3.1% | 3.4% | 4% |
The average Net Margin over the past 5 years is +8.3%.
The trend of Net Margin over the past 5 years is +1.01%.
The average ROA over the past 5 years is -0.02%.
The trend of ROA over the past 5 years is +1.02%.
The average ROE over the past 5 years is +3.75%.
The trend of ROE over the past 5 years is +0.54%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | -1.47 | -1.82 | -5.65 | -6.99 | -12.73 | -38.00 | 5.26 | 20.02 | 25.47 | 8.77 |
Debt Equity | 0.28 | 0.25 | 0.42 | 0.29 | 0.39 | 0.27 | 0.26 | 0.24 | 0.32 | 0.31 |
MIN | ||||||||||
Graham Stability | - | - | - | - | - | - | -25% | 55% | 54% | -25% |
The Debt/FCF trailing twelve month is 8.77.
The trend of Debt/FCF over the past 5 years is 8.68.
Graham’s Stability measure stands at -0.25.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | 12% | 10% | 9.1% | 15% | -1.5% |
Net Income | - | - | -42% | 18% | - |
Stockholders Equity | 8.7% | 11% | 6.4% | 7.6% | -3.2% |
FCF | - | - | - | 14% | 88% |
The Revenue CAGR over the past 5 years is +10.16%.
The trend of Revenue growth rate over the past 5 years is -1.49%.
The Earnings CAGR over the past 5 years is -.
The trend of Earnings growth rate over the past 5 years is -.
The Equity CAGR over the past 5 years is +10.78%.
The trend of Equity growth rate over the past 5 years is -3.16%.
The FCF CAGR over the past 5 years is -.
The trend of FCF growth rate over the past 5 years is +87.58%.